Web Exclusives

In a 4-arm randomized study, providing telephone genetic counseling only to those women who have a pathogenic mutation or who request the counseling is noninferior to mandatory pre- and posttest counseling, which may represent a new paradigm for genetic testing. Read Article ›

Selpercatinib Shows Durable Responses in Patients with Thyroid Cancer and RET Mutation
Venclexta plus Azacitidine Improves Overall Survival in Patients with AML
Advances in New Therapies Attributed to Reductions in Lung Cancer Mortality
Read Article ›

Initiating annual breast cancer screening at 40 years of age may reduce mortality rates in women, according to study results published August 12, 2020, in the journal The Lancet Oncology (Duffy SW, et al. Lancet Oncol. 2020;21:1165-1172). Starting earlier screening also did not result in overdiagnosis. Read Article ›

The results of an online questionnaire of 609 breast cancer survivors in the Unites States suggest that almost 50% experienced delays in care during the early weeks of the COVID-19 pandemic. The research was published online on August 9, 2020, in the journal Breast Cancer Research and Treatment (Papautsky EL, et al. Breast Cancer Res Treat. 2020 Aug 9. Epub ahead of print). Read Article ›

In the phase 2 OVARIO study, median progression-free survival has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities. Read Article ›

An all-oral regimen in women with recurrent platinum-sensitive ovarian cancer did not show superiority to platinum-based regimens on the outcome of progression-free survival. Read Article ›

In a meta-analysis of 7 large randomized clinical trials, PARP inhibitors were not significantly more likely to cause secondary hematologic malignancies compared with control groups. Read Article ›

A pooled analysis of 2 studies using rucaparib for the treatment of patients with recurrent high-grade ovarian cancer supported the approved starting dose of 600 mg twice daily. Read Article ›

A global phase 3 randomized study is currently enrolling patients with stage III or IV high-grade nonmucinous epithelial ovarian cancer to assess the efficacy of an investigational anti–PD-1 humanized monoclonal antibody plus standard of care as first-line treatment and maintenance. The primary outcome measure is progression-free survival. Read Article ›

It is a Herculean effort to develop a novel vaccine on an unprecedented timeline. Experts discuss the latest research regarding the development of vaccine candidates for the COVID-19 virus and some of the issues that will need to be addressed when a successful candidate has been identified, including clinical trial enrollment, manufacturing, and distribution. Read Article ›

Community oncology practices say they are recovering from the COVID-19 pandemic and keeping their eye on the goal of value-based care. The strategies they are using to accomplish these initiatives include innovation, long-term integration of telehealth, and the leveraging of advanced practice professionals. Read Article ›

The COVID-19 pandemic has created significant barriers to care, which can lead to increased mortality rates for thousands of patients with cancer. Nurses and nurse navigators are focused on using their skills and experience to combat this trend. Ongoing efforts include educating patients on the importance of undergoing cancer screenings, utilizing telehealth services to enhance communication with patients, addressing staffing shortages, and taking the necessary steps for preparing for potential spikes in COVID-19 cases. Read Article ›

Page 4 of 14

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: